Trial · NCT03452397
Adverse events76
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 76
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Eye pruritus | Eye disorders | 0.2 % Hemigalactarate (0.11% Free Base) 0.2 % OC-02 Low Dose (1.1 mg/mL) | 0 | 41 | |
| other | Eye pruritus | Eye disorders | 1.0 % Hemigalactarate (0.11% Free Base) 1.0 % OC-02 Mid Dose (5.5 mg/mL) | 0 | 41 | |
| other | Eye pruritus | Eye disorders | 2.0 % Hemigalactarate (0.11% Free Base) 2.0 % OC-02 High Dose (11.1 mg/mL) | 1 | 41 | |
| other | Eye pruritus | Eye disorders | Placebo (Vehicle) Nasal Spray | 0 | 42 | |
| other | Keratits | Eye disorders | 0.2 % Hemigalactarate (0.11% Free Base) 0.2 % OC-02 Low Dose (1.1 mg/mL) | 0 | 41 | |
| other | Keratits | Eye disorders | 1.0 % Hemigalactarate (0.11% Free Base) 1.0 % OC-02 Mid Dose (5.5 mg/mL) | 1 | 41 | |
| other | Keratits | Eye disorders | 2.0 % Hemigalactarate (0.11% Free Base) 2.0 % OC-02 High Dose (11.1 mg/mL) | 0 | 41 | |
| other | Keratits | Eye disorders | Placebo (Vehicle) Nasal Spray | 0 | 42 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | 0.2 % Hemigalactarate (0.11% Free Base) 0.2 % OC-02 Low Dose (1.1 mg/mL) | 8 | 41 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | 1.0 % Hemigalactarate (0.11% Free Base) 1.0 % OC-02 Mid Dose (5.5 mg/mL) | 10 | 41 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | 2.0 % Hemigalactarate (0.11% Free Base) 2.0 % OC-02 High Dose (11.1 mg/mL) | 15 | 41 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Placebo (Vehicle) Nasal Spray | 0 | 42 | |
| other | Throat irritation | Respiratory, thoracic and mediastinal disorders | 0.2 % Hemigalactarate (0.11% Free Base) 0.2 % OC-02 Low Dose (1.1 mg/mL) | 6 | 41 | |
| other | Throat irritation | Respiratory, thoracic and mediastinal disorders | 1.0 % Hemigalactarate (0.11% Free Base) 1.0 % OC-02 Mid Dose (5.5 mg/mL) | 10 | 41 | |
| other | Throat irritation | Respiratory, thoracic and mediastinal disorders | 2.0 % Hemigalactarate (0.11% Free Base) 2.0 % OC-02 High Dose (11.1 mg/mL) | 10 | 41 | |
| other | Throat irritation | Respiratory, thoracic and mediastinal disorders | Placebo (Vehicle) Nasal Spray | 0 | 42 | |
| other | Sneezing | Respiratory, thoracic and mediastinal disorders | 0.2 % Hemigalactarate (0.11% Free Base) 0.2 % OC-02 Low Dose (1.1 mg/mL) | 1 | 41 | |
| other | Sneezing | Respiratory, thoracic and mediastinal disorders | 1.0 % Hemigalactarate (0.11% Free Base) 1.0 % OC-02 Mid Dose (5.5 mg/mL) | 4 | 41 | |
| other | Sneezing | Respiratory, thoracic and mediastinal disorders | 2.0 % Hemigalactarate (0.11% Free Base) 2.0 % OC-02 High Dose (11.1 mg/mL) | 1 | 41 | |
| other | Sneezing | Respiratory, thoracic and mediastinal disorders | Placebo (Vehicle) Nasal Spray | 1 | 42 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03452397/events